Trial Type: Kidney and Bladder Cancer

A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Placebo Plus Nivolumab as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

A phase II study of Gemcitabine plus Cisplatin Chemotherapy in Patients with Muscle Invasive Bladder Cancer with Bladder Preservation for Those Patients in Whose tumors harbor deleterious DNA damage response (DDR) Gene Alterations

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

A Pilot Study of Degarelix in Combination with Neoadjuvant Gemcitabine and Cisplatin in Muscle-Invasive Urothelial Cell Carcinoma of the Bladder)

LS-P-SODA: Phase I study of antibody-drug-conjugate (DS-3939) targeting tumors expressing TA-MUC-1

First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Trial To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of Df6215 In Patients With Advanced (Unresectable, Recurrent, Or Metastatic) Solid Tumors

This drug causes immune activation by blocking PTPN2/N1. The study drug is given alone and in combination with PD-1 inhibitors. Cohorts in kidney cancer, head and neck, and other solid tumors.

inhibitor of MTAP for patients with MTAP gene alterations in gastric esophageal, NSCLC and bladder cancer